VCM
ALDX icon

Versant Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Versant Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-139
Closed -$235 – 2749
2026
Q1 		$235 Buy
+139
New +$609 ﹤0.01% 2754

Other funds holding ALDX

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Versant Capital Management's ALDX Position: Q2 2026 in Review

Versant Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 139 shares — an estimated $235 sold.

Versant Capital Management first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $235 in Q1 2026. 14 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Versant Capital Management reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 139 Aldeyra Therapeutics shares in Q2 2026, an estimated $235.
  • Versant Capital Management first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
  • Versant Capital Management's Aldeyra Therapeutics position peaked at $235 in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.